Credit Suisse Maintains Their Buy Rating on Johnson & Johnson

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Buy rating on Johnson & Johnson (NYSE: JNJ), with a price target of $151. The company’s shares closed yesterday at $125.93.

According to, Divan is a 1-star analyst with an average return of -1.3% and a 47.0% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Eli Lilly & Co, and Bristol Myers.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Johnson & Johnson with a $142.60 average price target, representing a 13.2% upside. In a report issued on July 10, BMO Capital also reiterated a Buy rating on the stock with a $150 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $148.32 and a one-year low of $118.62. Currently, Johnson & Johnson has an average volume of 6.49M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

From Our Partners